JP2008512479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512479A5 JP2008512479A5 JP2007531333A JP2007531333A JP2008512479A5 JP 2008512479 A5 JP2008512479 A5 JP 2008512479A5 JP 2007531333 A JP2007531333 A JP 2007531333A JP 2007531333 A JP2007531333 A JP 2007531333A JP 2008512479 A5 JP2008512479 A5 JP 2008512479A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- medicament according
- death receptor
- receptor
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 18
- 108010049207 Death Domain Receptors Proteins 0.000 claims 14
- 102000009058 Death Domain Receptors Human genes 0.000 claims 14
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 3
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 108700012411 TNFSF10 Proteins 0.000 claims 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60783404P | 2004-09-08 | 2004-09-08 | |
| US66655005P | 2005-03-30 | 2005-03-30 | |
| PCT/US2005/032015 WO2006029275A2 (en) | 2004-09-08 | 2005-09-07 | Methods of using death receptor ligands and cd20 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512479A JP2008512479A (ja) | 2008-04-24 |
| JP2008512479A5 true JP2008512479A5 (enExample) | 2008-10-23 |
Family
ID=35788041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531333A Pending JP2008512479A (ja) | 2004-09-08 | 2005-09-07 | デスレセプターリガンド及びｃｄ２０抗体の使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090175854A1 (enExample) |
| EP (1) | EP1802660A2 (enExample) |
| JP (1) | JP2008512479A (enExample) |
| KR (1) | KR20070050951A (enExample) |
| CN (1) | CN101048428A (enExample) |
| AU (1) | AU2005282397A1 (enExample) |
| BR (1) | BRPI0515604A (enExample) |
| CA (1) | CA2577828A1 (enExample) |
| IL (1) | IL181315A0 (enExample) |
| NO (1) | NO20071789L (enExample) |
| NZ (1) | NZ553171A (enExample) |
| RU (1) | RU2007112952A (enExample) |
| WO (1) | WO2006029275A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| EP1756162A1 (en) | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Receptor coupling agents and therapeutic uses thereof |
| WO2008066854A2 (en) * | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
| US9295736B2 (en) | 2007-09-24 | 2016-03-29 | Bar Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| KR101853702B1 (ko) | 2009-12-07 | 2018-05-03 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 항-종양 항체 치료를 향상시키는 방법 |
| DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69533863T2 (de) * | 1994-02-04 | 2006-02-16 | Bio Merieux | MSRV1 Virus der mit Multipler Sklerose verbunden ist, seine nukleären Bestandteile und Verwendungen |
| KR101004174B1 (ko) * | 1995-06-29 | 2010-12-24 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| ATE362982T1 (de) * | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| NZ337795A (en) * | 1997-03-17 | 2001-06-29 | Human Genome Sciences Inc | Death domain containing receptor 5 and it's use in the treatment of DR5 related disease |
| CA2287085A1 (en) * | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| IL137176A0 (en) * | 1998-01-26 | 2001-07-24 | Genentech Inc | Antibodies to 4dr and uses thereof |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| EP1401476A4 (en) * | 2001-03-14 | 2006-03-08 | Genentech Inc | IGF ANTAGONIST PEPTIDES |
| NZ533164A (en) * | 2001-11-01 | 2008-09-26 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
-
2005
- 2005-09-07 JP JP2007531333A patent/JP2008512479A/ja active Pending
- 2005-09-07 NZ NZ553171A patent/NZ553171A/en not_active IP Right Cessation
- 2005-09-07 KR KR1020077005375A patent/KR20070050951A/ko not_active Withdrawn
- 2005-09-07 RU RU2007112952/13A patent/RU2007112952A/ru not_active Application Discontinuation
- 2005-09-07 CN CNA2005800364755A patent/CN101048428A/zh active Pending
- 2005-09-07 BR BRPI0515604-1A patent/BRPI0515604A/pt not_active IP Right Cessation
- 2005-09-07 AU AU2005282397A patent/AU2005282397A1/en not_active Abandoned
- 2005-09-07 EP EP05795474A patent/EP1802660A2/en not_active Withdrawn
- 2005-09-07 CA CA002577828A patent/CA2577828A1/en not_active Abandoned
- 2005-09-07 WO PCT/US2005/032015 patent/WO2006029275A2/en not_active Ceased
- 2005-09-07 US US11/662,315 patent/US20090175854A1/en not_active Abandoned
-
2006
- 2006-10-03 US US11/542,330 patent/US20070231324A1/en not_active Abandoned
-
2007
- 2007-02-13 IL IL181315A patent/IL181315A0/en unknown
- 2007-04-04 NO NO20071789A patent/NO20071789L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008512479A5 (enExample) | ||
| JP2008513367A5 (enExample) | ||
| AU784971B2 (en) | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies | |
| Yano et al. | Defucosylated anti–CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sézary syndrome | |
| CN107660151B (zh) | 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途 | |
| Beckwith et al. | The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model | |
| KR20190123749A (ko) | 항-tigit 항체 | |
| Makita et al. | Mogamulizumab for the treatment of T-cell lymphoma | |
| JP2014501729A5 (enExample) | ||
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| JP2008513354A5 (enExample) | ||
| RU2007112952A (ru) | Способы применения лигандов рецепторов смерти и cd20-антител | |
| RS62260B1 (sr) | Kombinacije i njihova upotreba | |
| Ishida et al. | Antibody therapy for Adult T-cell leukemia–lymphoma | |
| JP2006528627A5 (enExample) | ||
| Georgakopoulou et al. | Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare | |
| CN113613678A (zh) | 使用抗cd30抗体药物缀合物疗法治疗外周t细胞淋巴瘤的方法 | |
| Xiao et al. | Targeting the CD47-SIRPα Axis: present therapies and the future for cutaneous T-cell lymphoma | |
| JP2021517144A (ja) | Ｃｄ４７遮断療法およびｃｄ３８抗体の組み合わせ | |
| EP4168449A1 (en) | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint | |
| Stanley et al. | Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infection | |
| Bhandari et al. | Novel applications of Rituximab in dermatological disorders | |
| Martin et al. | Phase I to III Trials of Anti–B Cell Therapy in Non–Hodgkin's Lymphoma | |
| Coleman et al. | The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines | |
| Leonard et al. | Novel agents for follicular lymphoma |